Frank Wang is a Partner of Haiwen & Partners based in Shanghai. Frank has over 20 years of experience as a chartered patent attorney and a China lawyer, with profound understanding of the current patent practice in China. Frank has been highly regarded by both clients and industry as an expert in the intellectual property areas.
Frank joined Haiwen in 2019 as a partner. Before joining Haiwen, he worked as a senior counsel at Bird & Bird in its Shanghai office from 2015 to 2017, as a partner at Fieldfisher in its Shanghai office from 2017 to 2019, during which he acted for dozens of important IP cases such as Nokia vs Huaqin for its patent infringement, Dow vs Luxi Chemical for its trade secret tort, patent infringement case on manufacturing method of API, etc..
Prior to private practice, Frank was a valued member at CNIPA and Patent Re-examination Board with over 8 years of practice and was awarded as Examination Star and Outstanding Civil Servant.
Frank excels in the IP litigation in Chinese courts and carried a number of patent and other IP cases to trial. He is especially adept at litigating disputes involving complex technology in areas including chemistry, pharmaceuticals, biotechnology, telecommunication, mechanics. Frank is highly experienced in handling and resolving IP disputes both domestically and internationally. Frank is also skilled in advising Chinese clients on mapping their IP protection strategies.
The representative cases dealt by Frank are listed as follow:
Acted on IP Due Diligence during M&A deals for the clients including Hillhouse Capital, Temasek, Lilly Asia Ventures, DCG, U.S.-China Green Fund, etc..
Provided expert opinions regarding IP related issues during the process of listing on the HKEX for the clients including Lepu biopharma Co., LTD., Lepu scientech medical technology (Shanghai) Co., LTD., Microtech Medical (Hangzhou) Co., LTD., Insight Lifetech Co., LTD., etc..
Successfully won the invalidation of Lenvatinib’s crystalline patent before CNIPA for Qilu Pharmaceutical.
Provided legal services on trade-mark registration, re-examination, and brand protection for GNC, JISSBON HEALTHCARE, WinTwin, etc..
Advised Teva, Abcam for FTO projects on their generic drug products, including Imatinib, Everolimus, etc..
Advised Sumitomo Pharmaceuticals (Suzhou) Co., LTD. on global IP protection issues.
Acted for Gooao in its patent infringement case;
Acted for Jinji Dyestuffs in its patent infringement case;
Acted for Arabica in its copyright infringement case;
Acted for Broad Institute's Chinese patent prosecution issues on its CRISPR technology.
Frank received his LLB degree from Fudan University in 2002 and received his LLM degree from China University of Political Science and Law in 2008.
Frank’s native language is Mandarin, and he speaks English fluently.
Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258
